ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Gradual Vs. Rapid Buprenorphine Detoxification - 2

This study has been completed.

Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
University of Vermont
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000220
  Purpose

The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.


Condition Intervention Phase
Opioid-Related Disorders
 Drug: Buprenorphine
 Phase I

Drug Information available for:   Buprenorphine    Buprenorphine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Double-Blind
Official Title:   Gradual Vs. Rapid Buprenorphine Detoxification

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Retention
  • Observed withdrawal rating
  • Opioid agonist rating
  • Opioid antagonist rating

Estimated Enrollment:   0
Study Start Date:   June 1991
Estimated Study Completion Date:   July 2001

  Eligibility
Ages Eligible for Study:   33 Years to 43 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Please contact site for information.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000220

Locations
United States, Vermont
Treatment Research Center    
      Burlington, Vermont, United States, 05401

Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Vermont

Investigators
Principal Investigator:     Warren Bickel, Ph.D.     University of Vermont    
  More Information


Publications:
Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13(3):33-45.
 

Study ID Numbers:   NIDA-06969-2, R01-06969-2
First Received:   September 20, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00000220
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Buprenorphine
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on December 03, 2008

U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services



Links to all studies - primarily for crawlers